Anthony J Giovinazzo is an internationally recognised expert in defending intellectual property, as well as developing and commercialising drugs. He was the co-founder and CEO of Cynapsus Therapeutics, a speciality pharmaceutical company that listed on the Nasdaq before being acquired for $841 million by Sunovion Pharmaceuticals. The all-cash deal represented a 120 per cent premium on the share price. For the last three years, the Canadian businessman has been chairman of Sublimity Therapeutics, a Dublin company previously known as Sigmoid Pharma. He took on the role after a number of international financiers agreed to invest €55 million to help the…

Want to continue reading?

Introductory offer: Sign up today and pay €200 for an annual membership, a saving of €50.

Subscribe

Cancel at any time.

Are you already a member? .